Dr. Reddy's Laboratories Ltd (Dr. Reddy's) manufactures and distributes active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company provides prescription, generics, branded generics and OTC products. The company's key markets include the US, India, Russia, and other countries of the former Soviet Union, and Europe.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Dr. Reddy's has undertaken several research and development initiatives, primarily focusing on the development of product formulations, process validation, bioequivalence testing, and other data needed to prepare a growing list of drugs equivalent to numerous brand name products. The company's R&D activities also include developing biologics products for emerging and highly regulated markets and developing chemical processes for synthesizing API for use in its Global Generics segment and for sales in the emerging and developed markets to third parties. As of March 31, 2025, the company had filed 111 Drug Master Files (DMFs) globally of which 14 were in the US, eight in Canada, eight in Europe, and 81 in other countries. In total, the company held 1,629 active DMFs worldwide, including 264 active US DMFs. As of March 2025, the company had more than 2,600 trademarks filed with the Registrar of Trademarks in India which are either registered or are pending registration. The company has also filed registration applications for non-US trademarks in other countries in which it operates. In FY2025, the company spent INR23,881 million on its R&D activities, which as a percentage of revenue stood at 7.3% and grew 23.4% YoY.